US Phytotherapy Reports Significant Efficacy in Initial Studies on Dengue Virus

ORLANDO, Fla., April 20, 2016 /PRNewswire/ -- US Phytotherapy Inc. ("USPI") today announces that it has completed crucial research in confirming efficacy of its drug candidate for dengue virus inhibition in the recently completed preliminary cell culture studies.

USPI's patented solution demonstrated a dose-dependent inhibition of dengue virus infectivity in three distinctly different models of dengue virus infection. These studies employed the serotype dengue virus 2. USPI is continuing with pre-clinical in vivo studies and is in pre-IND discussions with the FDA.

According to the Company, this is a critical first step in expanding beyond the theoretical patent and into a viable therapeutic solution for dengue that not only works but because its components are derived from all natural, generally regarded as safe, sources they pose no undue threat of misdiagnosis and can be formulated for children.

Dengue is a mosquito-borne viral disease that has rapidly spread to all regions in recent years. The infection causes flu-like illness, and occasionally develops into a potentially lethal complication called hemorrhagic dengue. Dengue virus is transmitted by female mosquitoes mainly of the species Aedes aegypti and, to a lesser extent, Ae. albopictus. This mosquito also transmits chikungunya, yellow fever and zika infection. Dengue is widespread throughout the tropics, with local variations in risk influenced by rainfall, temperature and unplanned rapid urbanization. One study, on the prevalence of dengue, estimates that 3.9 billion people, in 128 countries, are at risk of infection with dengue viruses. Not only is the number of cases increasing as the disease spreads to new areas, but explosive outbreaks are occurring.

About US Phytotherapy

US Phytotherapy is a research and development company based in the United States, dedicated to the discovery and advancement of natural, plant-based formulas which are safe and effective in their use as a treatment against invasive diseases.

The Company's innovative drug development strategy is to explore drug candidates by applying new cutting edge technology to medicinal plants developing solutions for modern clinical difficulties, where there is no drug available or an existing drug has unacceptable side effects.

Currently, the Company is developing drugs against a number of viral diseases including dengue fever, zika virus, chikungunya, yellow fever and malaria, among others.

Contacts
US Phytotherapy, Inc.
Scientific Enquiries: Bob Rosen, 407.668.6778 [email protected]
Business Development: Matt Rosen, 804.709.8444 [email protected]

SOURCE US Phytotherapy, Inc.